Superworth

Celldex Therapeutics EPS CLDX

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$4.35
Latest quarter, Q2 FY26
−$0.94
Fiscal year 2025
−$3.89

Celldex Therapeutics' earnings per share was −$4.35 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.94.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.89n/a
FY2024−$2.45n/a
FY2023−$2.91n/a
FY2022−$2.39n/a
FY2021−$1.64n/a
FY2020−$2.14n/a
FY2019−$3.63n/a
FY2018−$15.75n/a
FY2017−$11.10n/a
FY2016−$18.90n/a
FY2015−$19.65n/a
FY2014−$19.80n/a
FY2013−$15.45n/a
FY2012−$15.30n/a
FY2011−$17.10n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.94n/a−$4.35
Q1 FY26−$1.18n/a−$4.26
Q4 FY25−$1.22n/a−$3.89
Q3 FY25−$1.01n/a−$3.38
Q2 FY25−$0.85n/a−$3.01
Q1 FY25−$0.81n/a−$2.70
Q4 FY24−$0.71n/a−$2.45
Q3 FY24−$0.64n/a−$2.57
Q2 FY24−$0.54n/a−$2.74
Q1 FY24−$0.56n/a−$2.85
Q4 FY23−$0.83n/a−$2.91
Q3 FY23−$0.81n/a−$2.64

Against its peers

Companies in Medical - Diagnostics & Research nearest Celldex Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CLDXCelldex Therapeutics−$4.35
CDNACareDx$2.07+116% a year
VCYTVeracyte$1.40+324% a year
BLLNBillionToOne$0.65
LNTHLantheus$4.13+10% a year
CAICaris Life Sciences$0.37
BIOBio-Rad Laboratories$8.25−30% a year
NRCNRC Health$0.25−67% a year
RVTYRevvity$2.10−11% a year
MEDPMedpace$17.05+27% a year
Peer median$2.07

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Celldex Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.